
BDX Stock Forecast & Price Target
BDX Analyst Ratings
Bulls say
Becton Dickinson's positive outlook is supported by robust sales growth, with the Medical Surgical Systems (MMS) segment reporting $888 million in FQ3'25, reflecting a year-over-year increase of 5.3%, driven by strong demand in Infusion Systems and growth in Dispensing Solutions and Pharmacy Automation. The company's MedTech business has consistently achieved annual growth rates exceeding 6% since the launch of its BD 2025 initiative, coupled with improving margins, indicating strong operational efficiency and market positioning. Additionally, the Medical Device Solutions (MDS) segment demonstrated solid performance, with FY24 sales reaching $4.43 billion, representing a 3.2% increase year-over-year, further reinforcing the company's strong financial foundation in the healthcare sector.
Bears say
Becton Dickinson's organic revenue growth outlook has been downgraded from 4.0-4.5% to 3.0-3.5%, indicating a decline in expected sales performance. In FQ3'25, the company reported $1.25 billion in sales, a decrease of 1.1% year-over-year, attributed to low-single digit declines in the Biosciences and Diagnostic Solutions segments, along with stagnation in Specimen Management. Additional challenges include volume-based procurement headwinds in China and reduced demand in the Biosciences sector due to government cuts to research grants, which collectively exert pressure on revenue growth.
This aggregate rating is based on analysts' research of Becton, Dickinson and Co. and is not a guaranteed prediction by Public.com or investment advice.
BDX Analyst Forecast & Price Prediction
Start investing in BDX
Order type
Buy in
Order amount
Est. shares
0 shares